NewAmsterdam Pharma Company N.V. (NAMS) AI Stock Analysis
NAMS AI stock analysis summary
AI ResearchNewAmsterdam Pharma Company N.V. (NAMS) is a late-stage biopharmaceutical company developing obicetrapib for metabolic and cardiovascular diseases. Over the trailing twelve months, the company generated $7.1M in revenue and recorded net cash of $633.8M as of June 30, 2026. The stock has experienced a 1-year return of -45.6% while carrying a market cap of $2.37B.
- Market cap
- $2.37B
- Revenue (TTM)
- $7.1M
- P/E
- — fwd 119.0x
- 1Y return
- -45.6% S&P 500 16.8%
- Avg. target
- $49.93 151.8% vs last close
Bull case
- The consensus mean price target of $49.93 indicates a 151.8% potential increase from the last close of $19.83.
- NewAmsterdam Pharma maintains a strong balance sheet with $633.9M in cash and short-term investments and minimal total debt of $82,000 as of June 30, 2026.
- Analyst consensus projects next fiscal year revenue to grow 384.1% to $119.9M according to 12 analysts.
Bear case
- The company remains unprofitable, reporting an operating cash flow of -$147.8M and a net income of -$203.8M in FY2025.
- Dilution has been substantial, with the 5-year share count change expanding by 595.0%.
- The stock has experienced significant downward momentum, posting a 1-year return of -45.6% and trading 34.9% below its 200-day average.
What NewAmsterdam Pharma does
NewAmsterdam Pharma Company N.V., headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical firm focused on developing innovative therapies for metabolic diseases. The company is advancing a pipeline of therapeutic candidates led by obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib is undergoing clinical trials as a monotherapy and in combination with ezetimibe to lower LDL-C levels, targeting cardiovascular diseases. Furthermore, the company is evaluating obicetrapib in Phase 2a clinical trials for the treatment of Alzheimer's disease.
Growth and profitability
Revenue shifted from $102.7M in FY2022 to $14.1M in FY2023, rose to $45.6M in FY2024, and fell 50.6% to $22.5M in FY2025. Across the 3-year period from FY2022 to FY2025, revenue registered a CAGR of -39.7%. Net income was -$22.6M in FY2022, -$176.9M in FY2023, -$241.6M in FY2024, and -$203.8M in FY2025, while FY2025 rnd_expense reached $141.8M. Over the trailing twelve months ended June 30, 2026, revenue stood at $7.1M with an operating margin of -1752.6%, and quarterly revenue declined 80.7% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, NewAmsterdam Pharma held $633.9M in cash and short-term investments and total debt of $82,000, resulting in net cash of $633.8M. Shareholders' equity was $631.4M alongside total assets of $704.5M. The company maintains a current ratio of 9.03 and a debt_to_equity ratio of 0.00. Free cash flow was -$148.0M and operating cash flow was -$147.8M in FY2025. Capital expenditures totaled $246,000 for FY2025, while the share count increased 595.0% over 5 years.
Valuation and performance
NewAmsterdam Pharma carries a market cap of $2.37B and an enterprise value of $2.08B. The company trades at a forward P/E of 119.0x, compared to the US-listed Healthcare peer median of 17.3x. Its price-to-sales ratio is 332.9x, significantly above the peer median of 4.1x, while EV to EBITDA stands at 27.6x versus the peer median of 12.0x. Over the past year, the stock returned -45.6%, lagging the S&P 500 return of 16.8%. Over a 5-year period, the stock gained 102.6% compared to 83.0% for the S&P 500.
What analysts expect
Wall Street coverage consists of 12 Strong Buy, 3 Buy, and 1 Hold recommendations, with 0 Sell ratings. The mean price target is $49.93, representing an upside of 151.8% over the last close of $19.83. For the current fiscal year ending December 31, 2026, the consensus EPS estimate is -$1.66 on revenue of $24.8M. For the next fiscal year, 12 analysts project revenue of $119.9M and an EPS estimate of -$1.55. The company beat EPS estimates in 1 of the last 4 quarters, and the next earnings date is November 4, 2026.
Key risks and what to watch
- Revenue generation is volatile, having declined 50.6% in FY2025 and 80.7% year-over-year in the quarter ended June 30, 2026.
- Ongoing clinical development requires substantial resources, as reflected by FY2025 R&D expenses of $141.8M.
- Short interest represents 18.6% of the float, pointing to elevated skepticism in the market.
- The stock trades at a steep price-to-sales multiple of 332.9x compared to the US-listed Healthcare median of 4.1x.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this NAMS AI stock analysis
This page is an AI-written research summary of NewAmsterdam Pharma Company N.V. (NAMS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: NAMS income statement, NAMS balance sheet, NAMS key metrics, NAMS analyst forecast, NAMS chart. See the NAMS stock overview for the latest quote and news.
NAMS AI stock analysis FAQ
What is NewAmsterdam Pharma's lead drug candidate?
The company's primary candidate is obicetrapib, an oral low-dose CETP inhibitor being evaluated for cardiovascular diseases and in Phase 2a trials for Alzheimer's disease.
How much cash does NewAmsterdam Pharma have?
As of June 30, 2026, NewAmsterdam Pharma had $633.9M in cash and short-term investments against total debt of $82,000, resulting in net cash of $633.8M.
What are analysts' price targets for NAMS?
The mean price target is $49.93, which represents an upside of 151.8% from the last close of $19.83.
Does NewAmsterdam Pharma pay a dividend?
NewAmsterdam Pharma does not pay a dividend, and no dividend distribution is reported.
When is NewAmsterdam Pharma's next earnings report?
The company's next earnings date is scheduled for November 4, 2026.